|
1
|
Estey E and Dohner H: Acute myeloid
leukaemia. Lancet. 368:1894–1907. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Frohling S, Scholl C, Gilliland DG and
Levine RL: Genetics of myeloid malignancies: pathogenetic and
clinical implications. J Clin Oncol. 23:6285–6295. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Appelbaum FR, Gundacker H, Head DR, et al:
Age and acute myeloid leukemia. Blood. 107:3481–3485. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Downing JR: The core-binding factor
leukemias: lessons learned from murine models. Curr Opin Genet Dev.
13:48–54. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Scholl C, Gilliland DG and Frohling S:
Deregulation of signaling pathways in acute myeloid leukemia. Semin
Oncol. 35:336–345. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Kornblau SM, Womble M, Qiu YH, et al:
Simultaneous activation of multiple signal transduction pathways
confers poor prognosis in acute myelogenous leukemia. Blood.
108:2358–2365. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Steelman LS, Pohnert SC, Shelton JG,
Franklin RA, Bertrand FE and McCubrey JA: JAK/STAT, Raf/MEK/ERK,
PI3K/Akt and BCR-ABL in cell cycle progression and leukemogenesis.
Leukemia. 18:189–218. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Sangro B and Prieto J: Gene therapy for
liver cancer: clinical experience and future prospects. Curr Opin
Mol Ther. 12:561–569. 2010.PubMed/NCBI
|
|
9
|
Denefle PP: Introduction to gene therapy:
a clinical aftermath. Methods Mol Biol. 737:27–44. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Wadhwa PD, Zielske SP, Roth JC, Ballas CB,
Bowman JE and Gerson SL: Cancer gene therapy: scientific basis.
Annu Rev Med. 53:437–452. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Pfeifer A and Verma IM: Gene therapy:
promises and problems. Annu Rev Genomics Hum Genet. 2:177–211.
2001. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Qian C, Sangro B and Prieto J: New
strategies to enhance gene therapy efficiency. Gastroenterology.
123:639–642. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Wong HH, Lemoine NR and Wang Y: Oncolytic
viruses for cancer therapy: overcoming the obstacles. Viruses.
2:78–106. 2010. View
Article : Google Scholar : PubMed/NCBI
|
|
14
|
Qian C, Liu XY and Prieto J: Therapy of
cancer by cytokines mediated by gene therapy approach. Cell Res.
16:182–188. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Kirn D, Martuza RL and Zwiebel J:
Replication-selective virotherapy for cancer: biological
principles, risk management and future directions. Nat Med.
7:781–787. 2001. View
Article : Google Scholar : PubMed/NCBI
|
|
16
|
Singer O and Verma IM: Applications of
lentiviral vectors for shRNA delivery and transgenesis. Curr Gene
Ther. 8:483–488. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Berk AJ: Recent lessons in gene
expression, cell cycle control, and cell biology from adenovirus.
Oncogene. 24:7673–7685. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Zhang W, Cai R, Luo J, et al: The
oncolytic adenovirus targeting to TERT and RB pathway induced
specific and potent anti-tumor efficacy in vitro and in vivo for
hepatocellular carcinoma. Cancer Biol Ther. 6:1726–1732. 2007.
View Article : Google Scholar
|
|
19
|
Sherr CJ and McCormick F: The RB and p53
pathways in cancer. Cancer Cell. 2:103–112. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Cui Q, Jiang W, Wang Y, et al: Transfer of
suppressor of cytokine signaling 3 by an oncolytic adenovirus
induces potential antitumor activities in hepatocellular carcinoma.
Hepatology. 47:105–112. 2008. View Article : Google Scholar
|
|
21
|
Papadakis ED, Nicklin SA, Baker AH and
White SJ: Promoters and control elements: designing expression
cassettes for gene therapy. Curr Gene Ther. 4:89–113. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Luo J, Xia Q, Zhang R, et al: Treatment of
cancer with a novel dual-targeted conditionally replicative
adenovirus armed with mda-7/IL-24 gene. Clin Cancer Res.
14:2450–2457. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Segerman A, Mei YF and Wadell G:
Adenovirus types 11p and 35p show high binding efficiencies for
committed hematopoietic cell lines and are infective to these cell
lines. J Virol. 74:1457–1467. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Lyons M, Onion D, Green NK, et al:
Adenovirus type 5 interactions with human blood cells may
compromise systemic delivery. Mol Ther. 14:118–128. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Yu L, Shimozato O, Li Q, et al: Adenovirus
type 5 substituted with type 11 or 35 fiber structure increases its
infectivity to human cells enabling dual gene transfer in
CD46-dependent and -independent manners. Anticancer Res.
27:2311–2316. 2007.PubMed/NCBI
|
|
26
|
Pestka S, Krause CD, Sarkar D, Walter MR,
Shi Y and Fisher PB: Interleukin-10 and related cytokines and
receptors. Annu Rev Immunol. 22:929–979. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Lebedeva IV, Emdad L, Su ZZ, et al:
mda-7/IL-24, novel anticancer cytokine: Focus on bystander
antitumor, radiosensitization and antiangiogenic properties and
overview of the phase I clinical experience (Review). Int J Oncol.
31:985–1007. 2007.PubMed/NCBI
|
|
28
|
Fisher PB: Is mda-7/IL-24 a ‘magic bullet’
for cancer? Cancer Res. 65:10128–10138. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Sauane M, Gopalkrishnan RV, Sarkar D, et
al: MDA-7/IL-24: novel cancer growth suppressing and apoptosis
inducing cytokine. Cytokine Growth Factor Rev. 14:35–51. 2003.
View Article : Google Scholar
|
|
30
|
Qian W, Liu J, Tong Y, et al: Enhanced
antitumor activity by a selective conditionally replicating
adenovirus combining with MDA-7/interleukin-24 for B-lymphoblastic
leukemia via induction of apoptosis. Leukemia. 22:361–369. 2008.
View Article : Google Scholar
|
|
31
|
Zhao L, Dong A, Gu J, et al: The antitumor
activity of TRAIL and IL-24 with replicating oncolytic adenovirus
in colorectal cancer. Cancer Gene Ther. 13:1011–1022. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Aghi M and Martuza RL: Oncolytic viral
therapies - the clinical experience. Oncogene. 24:7802–7816. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Mathis JM, Stoff-Khalili MA and Curiel DT:
Oncolytic adeno-viruses - selective retargeting to tumor cells.
Oncogene. 24:7775–7791. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Wong HH, Jiang G, Gangeswaran R, et al:
Modification of the early gene enhancer-promoter improves the
oncolytic potency of adenovirus 11. Mol Ther. 20:306–316. 2012.
View Article : Google Scholar :
|
|
35
|
Segerman A, Atkinson JP, Marttila M,
Dennerquist V, Wadell G and Arnberg N: Adenovirus type 11 uses CD46
as a cellular receptor. J Virol. 77:9183–9191. 2003. View Article : Google Scholar : PubMed/NCBI
|
